Till Erdmann

Springboard Health Angels is a Berlin-based business angel group that invests in early-stage life sciences startups, with a focus on health tech

JUHI wurde im März 2018 in Berlin gegründet. Als deutschlandweit erster Anbieter unterstützen wir Pflegebedürftige im Alltag mit Schülern, Studierenden und Auszubildenden. Dadurch sind wir nicht nur die perfekte Job-Alternative für junge Menschen mit sozialer Einstellung sondern stellen auch die Verbindung zwischen Generationen wieder her. Dass dieses Konzept großen Zuspruch findet, zeigt uns tägliches Feedback unserer Helferinnen und Helfer sowie Kundinnen und Kunden.

Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs. Its lead compound, myelo001, is a small molecule that is effective on the hematogenesis. Its oral application is being investigated as a treatment for - chemotherapy-induced myelosuppression (CIM), including chemotherapy-induced neutropenia (CIN), chemotherapy-induced thrombocytopenia, and chemotherapy-induced lymphocytopenia - radiation-induced myelosuppression (RIM) - acute radiation syndrome (ARS).

Diametos develops the world's first and only medical device for snoring cause diagnosis based on sound analysis.

Treamid Therapeutics develops several patent-protected, new chemical entities for inflammatory respiratory and endocrine diseases.

Springboard Health Angels is a Berlin-based business angel group that invests in early-stage life sciences startups, with a focus on health tech

JUHI wurde im März 2018 in Berlin gegründet. Als deutschlandweit erster Anbieter unterstützen wir Pflegebedürftige im Alltag mit Schülern, Studierenden und Auszubildenden. Dadurch sind wir nicht nur die perfekte Job-Alternative für junge Menschen mit sozialer Einstellung sondern stellen auch die Verbindung zwischen Generationen wieder her. Dass dieses Konzept großen Zuspruch findet, zeigt uns tägliches Feedback unserer Helferinnen und Helfer sowie Kundinnen und Kunden.

Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. The nine-month program employs an objectives-based mentoring process to enhance the performance of technical founders who learn from the insights of experienced entrepreneurs, with the goal of maximizing equity-value creation. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto’s Rotman School of Management, the program has expanded and now has 11 sites across six countries: Toronto, Vancouver, Calgary, Montreal, Halifax, Paris, Madison, Seattle, Estonia, Berlin, and Melbourne. The program combines 5 elements to help companies transition from science projects to scalable and financeable companies: - An emphasis on objective-setting, helping companies focus on what’s most important to their business - Focused mentorship from experienced entrepreneurs who have founded, led, and sold significant tech companies - Technical advice from world-leading scientists, engineers, and economists - Hands-on support from top business students, who embed within the company to provide business support - Opportunities to raise capital, including angels and VCs from Europe and North America The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over CAD $35 billion in equity value.

Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs. Its lead compound, myelo001, is a small molecule that is effective on the hematogenesis. Its oral application is being investigated as a treatment for - chemotherapy-induced myelosuppression (CIM), including chemotherapy-induced neutropenia (CIN), chemotherapy-induced thrombocytopenia, and chemotherapy-induced lymphocytopenia - radiation-induced myelosuppression (RIM) - acute radiation syndrome (ARS).

Diametos develops the world's first and only medical device for snoring cause diagnosis based on sound analysis.